Jesus F San-Miguel

Summary

Affiliation: Universidad de Salamanca
Country: Spain

Publications

  1. doi request reprint Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone
    Jesus F San-Miguel
    Servicio de Hematologia, Hospital Universitario de Salamanca, CIC, IBMCC, Spain
    Clin Lymphoma Myeloma Leuk 11:38-43. 2011
  2. doi request reprint Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma
    Jesus F San Miguel
    Hospital Universitario Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain
    J Clin Oncol 31:448-55. 2013
  3. pmc Genomic analysis of high-risk smoldering multiple myeloma
    Lucía López-Corral
    Servicio de Hematología del Hospital Universitario de Salamanca y Centro de Investigación del Cáncer IBMCC USAl CIC, Universidad de Salamanca, Salamanca, Spain
    Haematologica 97:1439-43. 2012
  4. doi request reprint Multiple myeloma: treatment evolution
    Jesus F San Miguel
    Servicio de Hematologia, Hospital Universitatio de Salamanca, CIC, IBMCC USAL CSIC, Spain
    Hematology 17:S3-6. 2012
  5. pmc The DAC system and associations with multiple myeloma
    Enrique M Ocio
    University Hospital of Salamanca, Salamanca, Spain
    Invest New Drugs 28:S28-35. 2010
  6. doi request reprint Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
    J F San-Miguel
    Department of Hematology, Hospital Universitario CIC Universidad de Salamanca CSIC, Salamanca, Spain
    Leukemia 22:842-9. 2008
  7. doi request reprint Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    Jesus F San Miguel
    Hospital Universitario Salamanca, CIC, IBMCC USAL CSIC, Salamanca, Spain
    N Engl J Med 359:906-17. 2008
  8. ncbi request reprint Conventional diagnostics in multiple myeloma
    Jesus F San Miguel
    Servicio de Haematología, Hospital Universitario de Salamanca, Paseo de San Vicente 58 182, 37007, Salamanca, Spain
    Eur J Cancer 42:1510-9. 2006
  9. ncbi request reprint A practical update on the use of bortezomib in the management of multiple myeloma
    Jesus San Miguel
    Hematology Department, Hospital Clinico Universitario de Salamanca, Servicio de Hematologia, Paseo de San Vicente 58, Salamanca E 37007, Spain
    Oncologist 11:51-61. 2006
  10. ncbi request reprint Analysis of methylation pattern in multiple myeloma
    Jesús San-Miguel
    Servicio de Hematologia, Hospital Universitario de Salamanca, Centro de Investigacion del Cancer, Universidad de Salamanca, Salamanca, Spain
    Acta Haematol 114:23-6. 2005

Detail Information

Publications36

  1. doi request reprint Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone
    Jesus F San-Miguel
    Servicio de Hematologia, Hospital Universitario de Salamanca, CIC, IBMCC, Spain
    Clin Lymphoma Myeloma Leuk 11:38-43. 2011
    ..In both trials the treatment was continued until disease progression or unacceptable toxicity. We conducted a subanalysis to determine if continuing therapy after achieving≥partial response (PR) improved survival...
  2. doi request reprint Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma
    Jesus F San Miguel
    Hospital Universitario Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain
    J Clin Oncol 31:448-55. 2013
    ....
  3. pmc Genomic analysis of high-risk smoldering multiple myeloma
    Lucía López-Corral
    Servicio de Hematología del Hospital Universitario de Salamanca y Centro de Investigación del Cáncer IBMCC USAl CIC, Universidad de Salamanca, Salamanca, Spain
    Haematologica 97:1439-43. 2012
    ..These findings suggest that gene expression profiling is a valuable technique to identify smoldering myeloma patients with high risk of progression. (Clinical Trials NCT00443235)...
  4. doi request reprint Multiple myeloma: treatment evolution
    Jesus F San Miguel
    Servicio de Hematologia, Hospital Universitatio de Salamanca, CIC, IBMCC USAL CSIC, Spain
    Hematology 17:S3-6. 2012
    ....
  5. pmc The DAC system and associations with multiple myeloma
    Enrique M Ocio
    University Hospital of Salamanca, Salamanca, Spain
    Invest New Drugs 28:S28-35. 2010
    ..This has prompted the development of combinations such as the one with bortezomib or lenalidomide and dexamethasone, which have already been taken into the clinics with positive preliminary results...
  6. doi request reprint Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
    J F San-Miguel
    Department of Hematology, Hospital Universitario CIC Universidad de Salamanca CSIC, Salamanca, Spain
    Leukemia 22:842-9. 2008
    ..These results indicate that bortezomib is active and well tolerated in patients with relapsed MM with varying degrees of renal insufficiency. Efficacy/safety were not substantially affected by severe-to-moderate vs no/mild impairment...
  7. doi request reprint Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    Jesus F San Miguel
    Hospital Universitario Salamanca, CIC, IBMCC USAL CSIC, Salamanca, Spain
    N Engl J Med 359:906-17. 2008
    ..This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible for high-dose therapy...
  8. ncbi request reprint Conventional diagnostics in multiple myeloma
    Jesus F San Miguel
    Servicio de Haematología, Hospital Universitario de Salamanca, Paseo de San Vicente 58 182, 37007, Salamanca, Spain
    Eur J Cancer 42:1510-9. 2006
    ..In addition, possible technical pitfalls inherent to each technique will be analysed...
  9. ncbi request reprint A practical update on the use of bortezomib in the management of multiple myeloma
    Jesus San Miguel
    Hematology Department, Hospital Clinico Universitario de Salamanca, Servicio de Hematologia, Paseo de San Vicente 58, Salamanca E 37007, Spain
    Oncologist 11:51-61. 2006
    ..Information is given on the practical management of the most common adverse events, including peripheral neuropathy and thrombocytopenia, and the use of bortezomib in renal and hepatic impairment...
  10. ncbi request reprint Analysis of methylation pattern in multiple myeloma
    Jesús San-Miguel
    Servicio de Hematologia, Hospital Universitario de Salamanca, Centro de Investigacion del Cancer, Universidad de Salamanca, Salamanca, Spain
    Acta Haematol 114:23-6. 2005
    ..Multiple myeloma remains an incurable disease, so new treatment strategies are needed to improve the outcome of patients...
  11. ncbi request reprint Prognostic features of multiple myeloma
    Jesus F San Miguel
    Department of Hematology, University Hospital of Salamanca, Paseo de San Vicente, 58 182, Salamanca 37007, Spain
    Best Pract Res Clin Haematol 18:569-83. 2005
    ....
  12. doi request reprint Risk stratification in the era of novel therapies
    Jesús San-Miguel
    Servicio de Hematologia, Hospital Universitario de Salamanca, Paseo de San Vicente, 58, Salamanca 37007, Spain
    Cancer J 15:457-64. 2009
    ....
  13. ncbi request reprint Myeloma: update on supportive care strategies
    Jesus F San Miguel
    Department of Hematology, University Hospital of Salamanca, Paso de San Vicente 52 182, 37007 Salamanca, Spain
    Curr Treat Options Oncol 4:247-58. 2003
    ..However, in MM, several specific adjuvant therapies have also been introduced (eg, bisphosphonates and erythroid-stimulating factors), which have conferred a key role to supportive therapy in the general treatment of patients with MM...
  14. doi request reprint Individualizing treatment of patients with myeloma in the era of novel agents
    Jesús San-Miguel
    Servicio de Hematologia, Hospital Universitario de Salamanca, Paseo de San Vicente, 58, 37007 Salamanca, Spain
    J Clin Oncol 26:2761-6. 2008
    ....
  15. pmc In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
    Enrique M Ocio
    Department of Hematology, University Hospital and Cancer Research Center, University of Salamanca P San Vicente, 58 182, 37007 Salamanca, Spain
    Haematologica 95:794-803. 2010
    ..We explored the antimyeloma activity of triple combinations of these well-established schemes with panobinostat, a novel deacetylase inhibitor with a multi-targeted profile...
  16. doi request reprint The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients
    Bruno Paiva
    Hospital Universitario de Salamanca, Salamanca, Spain
    Blood 114:4369-72. 2009
    ..This trial was registered at www.clinicaltrials.gov as NCT00560053...
  17. doi request reprint Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma
    Jesus F San-Miguel
    Jesús F San Miguel and María Victoria Mateos, Servicio e Hematologia, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Institut de Bilogia Molecular de Barcelona Universidad de Salamanca Spanish National Research Council, Salamanca Joan Bladé, Hospital Clinic de Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain Paul G Richardson and Kenneth C Anderson, Dana Farber Cancer Institute, Boston, MA David Siegel, Hackensack University Medical Center, Hackensack Kaushal K Mishra and Song Mu, Novartis Pharmaceuticals Corporation, East Hanover, NJ Andreas Günther, University of Kiel, Kiel Orhan Sezer, Charite Universitatsmedizin Berlin, Berlin, Germany Richard LeBlanc, Maisonneuve Rosemont Hospital, Montreal, Quebec Heather Sutherland, Vancouver General Hospital, Vancouver, British Columbia, Canada and Monika Sopala and Priscille M Bourquelot, Novartis Pharma AG, Basel, Switzerland
    J Clin Oncol 31:3696-703. 2013
    ..This phase Ib study sought to determine the maximum-tolerated dose (MTD) of panobinostat plus bortezomib in patients with relapsed or relapsed and refractory MM...
  18. doi request reprint Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs
    Enrique M Ocio
    University of Salamanca, University Hospital and Cancer Research Center, Department of Hematology, Salamanca, Spain
    Expert Opin Investig Drugs 21:1075-87. 2012
    ....
  19. ncbi request reprint Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
    Maria Victoria Mateos
    Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer Universidad de Salamanca Consejo Superior de Investigaciones Científicas, Salamanca, Spain
    Blood 120:2581-8. 2012
    ..In summary, these maintenance regimens result in a significant increase in CR rate, remarkably long PFS, and acceptable toxicity profile. The trial is registered at www.clinicaltrials.gov as NCT00443235...
  20. pmc Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients
    Maria E Sarasquete
    Servicio de Hematologia, Hospital Universitario, Centro de Investigación del Cáncer IBMCC USAL CSIC, Salamanca, Spain
    Haematologica 96:468-71. 2011
    ..02). By contrast, no differences in the expression of Drosha among these groups of patients were observed. Our data suggest that Dicer expression may play an important role in the progression and prognosis of monoclonal gammopathies...
  21. doi request reprint New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings
    Enrique M Ocio
    Servicio de Hematologia, Hospital Universitario de Salamanca, Salamanca, Spain
    Lancet Oncol 9:1157-65. 2008
    ..Unfortunately, the single-agent clinical activity of most of these new drugs has been limited; nevertheless, their effectiveness might be enhanced by their rational combination with each other or with conventional agents...
  22. pmc Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response
    Enrique Colado
    Centro de Investigacion del Cancer, IBMCC CSIC Universidad de Salamanca, Salamanca, Spain
    Haematologica 96:687-95. 2011
    ..We investigated the antileukemic activity and mechanism of action of zalypsis, a novel alkaloid of marine origin...
  23. pmc Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry
    Roberto J Pessoa de Magalhães
    Hospital Universitario de Salamanca, Salamanca, Spain
    Haematologica 98:79-86. 2013
    ....
  24. doi request reprint Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines
    Teresa Paíno
    Centro de Investigacion del Cancer, Instituto de Biología Molecular y Celular del Cáncer Consejo Superior de Investigaciones Científicas Universidad de Salamanca, Salamanca, Spain Instituto de Investigación Biomédica de Salamanca IBSAL, Salamanca, Spain
    PLoS ONE 9:e92378. 2014
    ..Future characterization of clonal plasma cell subpopulations in MM patients' samples will guarantee the discovery of more reliable markers able to discriminate true clonogenic myeloma cells...
  25. ncbi request reprint Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML)
    Jesus F San-Miguel
    Department of Haematology, University Hospital of Salamanca, Paseo de San Vicente 58 182, 37007 Salamanca, Spain
    Best Pract Res Clin Haematol 15:105-18. 2002
    ..Although reported data in the literature are still scanty, several authors have shown that this technique could be used for the prognostic evaluation of AML patients, when immunophenotypic evaluation is applied after induction therapy...
  26. ncbi request reprint Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value
    Maria Belen Vidriales
    Department of Hematology, University Hospital, Salamanca, Spain
    Blood 101:4695-700. 2003
    ....
  27. ncbi request reprint Immunologic monitoring in adults with acute lymphoblastic leukemia
    Maria Belen Vidriales
    Hematology Department, University Hospital of Salamanca, Paseo de San Vicente 58 182, 37007 Salamanca, Spain
    Curr Oncol Rep 5:413-8. 2003
    ....
  28. doi request reprint Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks
    Enrique M Ocio
    Centro de Investigacion del Cancer, Instituto de Biologia Molecular y Celular del Cancer Centro de Superior de Investigaciones Cientificas Universidad de Salamanca, Spain
    Blood 113:3781-91. 2009
    ..The potent in vitro and in vivo antimyeloma activity of Zalypsis uncovers the high sensitivity of tumor plasma cells to DSBs and strongly supports the use of this compound in MM patients...
  29. ncbi request reprint Minimal residual disease monitoring by flow cytometry
    María B Vidriales
    Department of Haematology, University Hospital, Paseo de San Vicente 58 182, 37007, Salamanca, Spain
    Best Pract Res Clin Haematol 16:599-612. 2003
    ..Current knowledge indicates that MRD studies using well-tested methodologies are clinically useful and should be incorporated into the clinical management of patients with acute leukaemia...
  30. doi request reprint Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission
    Leonor Puchades-Carrasco
    Structural Biochemistry Laboratory, Centro de Investigacion Principe Felipe, Valencia, Spain
    Clin Cancer Res 19:4770-9. 2013
    ..In this study, we aimed to evaluate the potential of metabolomics by (1)H-NMR to provide information on metabolic profiles that could be useful in the management of multiple myeloma...
  31. doi request reprint New tools for diagnosis and monitoring of multiple myeloma
    Jesus F San-Miguel
    From the Hospital Universitario de Salamanca, Salamanca, Spain IBSAL, IBMCC USAL CSIC, Salamanca, Spain
    Am Soc Clin Oncol Educ Book 2013:313-8. 2013
    ..In addition, possible technical pitfalls inherent to each technique will be analyzed...
  32. ncbi request reprint Influence of the different CD34+ and CD34- cell subsets infused on clinical outcome after non-myeloablative allogeneic peripheral blood transplantation from human leucocyte antigen-identical sibling donors
    Pablo Menendez
    Servicio General de Citometria, Departamento de Medicina and Centro de Investigaciones del Cáncer, Universidad de Salamanca, Spain
    Br J Haematol 119:135-43. 2002
    ..However, they also strongly impair clinical outcome by increasing the incidence of GVHD...
  33. doi request reprint Limbus damage in ocular graft-versus-host disease
    Rebeca Lorenzo Pérez
    Servicio de Oftalmologia, Universidad de Salamanca, Salamanca, Spain
    Biol Blood Marrow Transplant 17:270-3. 2011
    ..Our results represent a major finding that allows us to define a model for evaluating new therapeutic strategies for treating ocular GVHD prior to their use in clinical setting...
  34. ncbi request reprint Bone remodelation markers are useful in the management of monoclonal gammopathies
    Jose M Hernandez
    Department of Hematology, Hospital General of Segovia, Spain
    Hematol J 5:480-8. 2004
    ..01). BRM and BFM, especially the ratios, are useful in the evaluation of bone lesions in patients with monoclonal gammopathies...
  35. doi request reprint Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma
    Bruno Paiva
    Hospital Universitario de Salamanca, Salamanca, Spain
    J Clin Oncol 29:1627-33. 2011
    ..To investigate the impact of immunophenotypic response (IR) versus complete response (CR) and CR plus normal serum free light chain (sFLC) ratio (stringent CR) in elderly patients with multiple myeloma (MM) treated with novel agents...
  36. doi request reprint The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
    Enrique Colado
    Department of Haematology, Hospital Universitario de Salamanca, Salamanca, Spain
    Haematologica 93:57-66. 2008
    ..We investigated the effects of bortezomib on the growth and survival of AML cells...